BIO-B
Bio-Rad Laboratories, Inc.
Set alert
- YTD
- +22.14%
- 1 year
- +25.19%
- Open
- 379.50
- Prev close
- 379.50
- Mkt cap
- 10.15B
- Vol
- 13
- Avg vol
- 9
- EPS
- 7.89
- P/E
- 48.10
- Div yield
- 0.00%
More statistics
- Low
- 379.50
- High
- 379.50
- Forward P/E
- 0.00
- Beta
- 1.07
- Short ratio
- 1.00
- Inst. own
- 0.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 365.78
- 200-d avg
- 310.70
- 1y target
- 0.00
News
1 year ago seekingalpha.com
Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth…
1 year ago benzinga.com
Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
Bio-Rad Laboratories, Inc. BIO reported better-than-expected second-quarter financial results on Thursday.
2 years ago reuters.com
Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit
Diagnostics firm Bio-Rad Laboratories posted third-quarter profit above Wall Street estimates on Wednesday, helped by a recovery in demand for analytical tools from its biotech clients and steady…
2 years ago reuters.com
Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products
Bio-Rad Laboratories cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients.
2 years ago reuters.com
Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip
Diagnostics firm Bio Rad Laboratories reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China.
3 years ago reuters.com
Bio-Rad Labs cuts 2023 revenue growth forecast as biotechs cut spending
Bio-Rad Laboratories on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro challenges, sending the company's shares…